2.2 Study selection
No time or language restriction was applied. Inclusion criteria were as
follows: (1) Types of Studies: retrospective, prospective,
observational, descriptive or case-control studies reporting COVID-19
patients (<18 years) with the multisystem inflammatory
syndrome; (2) Subjects: diagnosed patients with COVID-19 (3) Exposure
intervention: COVID-19 patients diagnosed with Real-Time polymerase
chain reaction, radiological imaging, or both with at least 4 out of 5
principal features of typical Kawasaki syndrome (apart of the persistent
fever at least for five days): (i) bilateral conjunctival injection,
(ii) oral changes such as cracked and erythematous lips and strawberry
tongue, (iii) cervical lymphadenopathy, (iv) extremity changes such as
erythema or palm and sole desquamation, and (v) polymorphous rash.
Patients presented with fever lasting five or more days and with 2-3 of
these findings were considered as incomplete (atypical) Kawasaki
disease18; and (4) Outcome indicator: the mean and
standard deviation or median and interquartile range for COVID-19
related complications and mortality.
The following exclusion criteria were considered: (1) Case reports,
reviews, editorial materials, conference abstracts, summaries of
discussions, (2) Insufficient reported data information; or (3) In
vitro or in vivo studies.